Definium Therapeutics, Inc.
NASDAQDefinium Therapeutics enters the last week of June with one of the most dramatic moves in small-cap biotech this month — a 50% weekly gain driven by Phase 3 trial results for DT120, its lead psychiatric drug candidate, that landed a reported 47.8% single-day move on June 22. The analyst community moved fast. In the 72 hours following the data release, five firms raised their price…
Snapshot as of 24 Jun 2026
Definium Therapeutics enters the last week of June with one of the most dramatic moves in small-cap biotech this month — a 50% weekly gain driven by Phase 3 trial results for DT120, its lead psychiatric drug candidate,…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DFTX — free to start on ORTEX.
Sign up for free →Open DFTX on ORTEX